Cellectis S.A. develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors.The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia.
